Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00231582 | High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II | PHASE2 | COMPLETED | 50 | — | — | Sep 1, 2004 | Jan 1, 2010 | Feb 25, 2011 | 1 | France |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 1 |
| Name | Type | Description |
|---|---|---|
| epirubicin | DRUG | epirubicin |
| high-dose and autologous stem cell transplantation | PROCEDURE | high-dose and autologous stem cell transplantation |
| paclitaxel | DRUG | paclitaxel |
| etoposide | DRUG | etoposide |
| ifosfamide | DRUG | ifosfamide |
| carboplatin | DRUG | carboplatin |
Inclusion Criteria: Eligibility requirements includes the following criteria: * Age \>18 years and \< 65 * Performance status \< 3 * Histologically or biologically documented GCTs * Testicular, abdominal, or mediastinal tumors * Measurable or evaluable disease * Life expectancy \> 3 months * Norma...